Deng Jiang, Xiao Jun, Ma Ping, Gao Bo, Gong Feng, Lv Liping, Zhang Yanyu, Xu Jinbo
Beijing Key Laboratory of Blood Safety and Supply Technologies, Beijing 100850, China.
Beijing Institute of Transfusion Medicine, 27 (9) Taiping Road, Beijing 100850, China.
Viruses. 2017 May 19;9(5):118. doi: 10.3390/v9050118.
Cytomegalovirus (CMV) infection leads to notable morbidity and mortality in immunosuppressed patients. Current antiviral drugs are effective but seriously limited in their long-term use due to their relatively high toxicity. In the present study, we characterized the expression of murine CMV microRNAs (MCMV miRNAs) both in vitro and in vivo. Although 29 miRNAs were detectable during in vitro infection, only 11 miRNAs (classified as Group 1) were detectable during in vivo infection, and as many as 18 viral miRNAs (classified as Group 2) were less detectable (<50% of animals) in both the liver and lungs. In addition, viral miRNA profiles in the blood revealed unstable and reduced expression. We next explored the in vitro effects of viral miRNAs on MCMV replication. The inhibition of Group 1 viral miRNAs had little effect on virus production, but transfected cells overexpressing miR-m01-3-5p, miR-M23-1-5p, miR-M55-1, and miR-m107-1-5p in Group 2 showed statistically lower viral loads than those transfected with control miRNA (29%, 29%, 39%, and 43%, respectively, versus control). Finally, we performed hydrodynamic injection of viral miRNA agomirs and observed lower levels of MCMV recurrence in the livers of animals overexpressing the miR-m01-3-5p or mcmv-miR-M23-1-5p agomirs compared with those of animals transfected with control agomir, confirming the antiviral effects of viral miRNA manipulation in vivo. Therefore, the manipulation of viral miRNA expression shows great therapeutic potential and represents a novel antiviral strategy for the miRNA-based treatment of cytomegalovirus infection.
巨细胞病毒(CMV)感染在免疫抑制患者中会导致显著的发病率和死亡率。目前的抗病毒药物虽然有效,但由于其相对较高的毒性,长期使用受到严重限制。在本研究中,我们对小鼠巨细胞病毒微小RNA(MCMV miRNAs)在体外和体内的表达进行了表征。虽然在体外感染期间可检测到29种miRNAs,但在体内感染期间仅可检测到11种miRNAs(归类为第1组),多达18种病毒miRNAs(归类为第2组)在肝脏和肺中均较难检测到(<50%的动物)。此外,血液中的病毒miRNA谱显示表达不稳定且降低。接下来,我们探讨了病毒miRNAs对MCMV复制的体外影响。抑制第1组病毒miRNAs对病毒产生的影响很小,但在第2组中过表达miR-m01-3-5p、miR-M23-1-5p、miR-M55-1和miR-m107-1-5p的转染细胞显示,其病毒载量在统计学上低于转染对照miRNA的细胞(分别为29%、29%、39%和43%,与对照相比)。最后,我们进行了病毒miRNA激动剂的流体动力学注射,观察到与转染对照激动剂的动物相比,过表达miR-m01-3-5p或mcmv-miR-M23-1-5p激动剂的动物肝脏中MCMV复发水平较低,证实了体内病毒miRNA操纵的抗病毒作用。因此,操纵病毒miRNA表达具有巨大的治疗潜力,代表了一种基于miRNA治疗巨细胞病毒感染的新型抗病毒策略。